

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Name of Product: Polar Capital Global Healthcare Trust plc, Ordinary Shares

PRIP Manufacturer: Polar Capital LLP

ISIN: GB00B6832P16

Website: www.polarcapitalglobalhealthcaretrust.co.uk

Call +44 (0) 20 7227 2700 for more information.

The Financial Conduct Authority (FCA) is responsible for supervising Polar Capital LLP in relation to this Key Information Document. This Key Information Document is accurate as at 31 December 2023.

What is this product?

Type

Polar Capital Global Healthcare Trust Plc (the "Company") is a closed-ended investment company, incorporated as a public limited company in England and Wales. The Company has investment trust status. The Company's Shares are listed and traded on the London Stock Exchange ("LSE").

Objectives

The Company aims to generate capital growth by investing in a global portfolio of healthcare stocks spanning the pharmaceutical, medical services, medical devices and biotechnology sub-sectors. The Portfolio Manager may use financial derivatives (complex instruments based upon the value of underlying assets) to help achieve the Company's investment objective and to manage exposure to risk.

Intended Retail Investor

This product is intended for all investors (including those with a basic level of investment knowledge) who are seeking a return

on their investment and who can accept the risk of losing some or all of their original investment. The product should be considered a long-term investment, defined as five years or more.

This is an Alternative Investment Fund (AIF) product.

Depository HSBC Bank Plc, 8 Canada Square, London E14 5HQ. The Company's share price is listed on the LSE, this can be found at www.londonstockexchange.co.uk. Further information and corporate documentation including the latest and historic Annual and Interim Reports, can be obtained from the Company's website:

www.polarcapitalglobalhealthcaretrust.co.uk

Term

In the absence of any prior proposals, the articles of association require the directors to put forward at the first AGM after 1 March 2025, a resolution to place the Company into voluntary liquidation.

What are the risks and what could I get in return?

Risk Indicator



The risk indicator assumes that you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class.

This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact the capacity of the PRIIPs manufacturer to pay you.

Shares in closed-ended funds are listed on a stock exchange. In unusual market conditions, it may be difficult to find a buyer. This means it might not be possible to sell the shares when desired.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

Concentration Risk – the Company invests in a relatively concentrated number of companies based in the healthcare sector. This focused strategy can produce high gains but can also lead to significant losses. The Company is specialist in nature and therefore may be less diversified than other investment funds.

Investment Risk – the Company invests in company shares globally, and share prices can rise or fall due to a number of factors affecting global stock markets.

Derivative Risk – certain derivatives may result in gains or losses that are greater than the original amount invested. Derivatives also involve counterparty risk, which is the risk that a counterparty to the derivative contract cannot meet its contractual obligations.

Currency Risk – the Company invests in assets denominated in currencies other than the Company's base currency. Changes in exchange rates may have a negative impact on the Company's investments.

Investment performance information

Returns on your investment will be determined by the performance of the shares of the Company and dividends generated. Performance may be positive or negative depending on a number of factors outlined below. Geographical, political and macroeconomic events can impact the Company's performance. Due to its focus on the healthcare sector, the portfolio is more sensitive to investor sentiment.

Following the restructure of the Company in June 2017, the Company maintains long-term structural gearing in the form of a loan from the wholly owned subsidiary PCGH ZDP Plc. No short-term borrowings have been made and there are no arrangements made for any bank loans. The Articles of Association provide that the Company may borrow up to 15% of its Net Asset Value at the time of drawdown, for tactical deployment when the Board believes (on the recommendation of the Portfolio Manager) that gearing will enhance returns to shareholders. Whilst the use of gearing is intended to enhance the NAV total return, it will have the opposite effect when the return on the Company's investment portfolio is negative. The degree of risk which the Portfolio Manager incurs in order to generate the investment returns and the effect of gearing on the portfolio by borrowed funds can affect the portfolio returns per share positively or negatively.

The Company will measure the Portfolio Manager's performance against the MSCI ACWI Healthcare Index ('the Benchmark') total return, in sterling with dividends reinvested. Although the Company has a benchmark, this is neither a target nor determinant of investment strategy. The portfolio may diverge substantially from the constituents of this index. The purpose of the benchmark is to set a reasonable measure of performance for shareholders above which the Portfolio Manager earns a share for any outperformance it has delivered.

What could affect my return positively?

Returns can be positively influenced by a number of factors. These include strong stock selection by the Company's Portfolio Manager, their ability to make good investment decisions, performance of the underlying stocks led by a good macroeconomic environment. Good investor sentiment towards healthcare may also impact returns positively.

What could affect my return negatively?

Poor macroeconomic conditions can lead to market volatility and result in negative performance of underlying stocks, negatively impacting shareholder returns. Local taxes, fluctuating exchange rates and regulatory intervention or underlying Company policy changes can also have a material impact on returns. Poor investment decisions and stock selection from the Portfolio Manager can adversely affect returns. Poor performance of the healthcare industry or investor sentiment can also impact shareholders.

Under adverse market conditions, share prices may fall. If you decide to sell your shares, you may get back less than the amount initially invested.

What happens if the Company is unable to pay out?

As the shares are not traded directly with the Company or the Investment Manager but are traded on the LSE, any default by the Investment Manager will not materially affect the value of your shares. However, a default by the Company or any of the underlying holdings could affect the value of your investment. As the shares are listed on the LSE, any direct holding of these shares is not covered by any investor compensation schemes in relation to either the Investment Manager or the Company.

The depository, HSBC Bank plc, is responsible for the safekeeping of your assets. You may face a financial loss if HSBC Bank plc defaults on its obligations. There is no compensation or guarantee scheme in place to offset all, or any of, this loss.

What are the costs?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs.

The amounts shown here are the cumulative costs of the product itself, for three different holding periods. They include potential early exit penalties. The figures assume you invest GBP 10,000. The figures are estimates and may change in the future.

Costs over time

The person selling you or advising you about this product may charge you other costs. If so, this person will provide you with information about these costs, and show you the impact that all costs will have on your investment over time.

The table below shows:

- the impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period;
- the meaning of the different cost categories.

	If you cash in after 1 year	If you cash in after 3 years	If you cash in after 5 years
Total costs	114.26 £	367.70 £	657.43 £
Impact on return (RIY) per year	1.14%	1.14%	1.14%

Composition of costs

This table shows the impact on return per year			
One-off costs	Entry costs	0.00%	We do not charge an entry fee for this product.
	Exit costs	0.00%	We do not charge an exit fee for this product.
Ongoing costs	Portfolio transaction costs	0.35%	The impact of the costs of us buying and selling underlying investments for the product.
	Other ongoing costs	0.79%	The costs that we take each year for managing your investment.
Incidental costs	Performance fees	0.00%	The Manager may be entitled to a performance fee, payable at the end of the Company's expected life. Such fee is calculated by pre-determined conditions, full information is provided in the Company's Strategic Report within the latest published Annual Report.
	Carried interest	0%	There are no carried interests.

Figures may not sum due to rounding

How long should I hold it and can I take money out early?

Recommended holding period: 5 years

The Company's shares are listed on the LSE. If you require information on how you can sell your shares, please refer to your investment platform, stockbroker or the Company's registrar, Equiniti Limited, shareholder line 0800 3134922. Further information is available within the Company's Annual Report.

How can I complain?

If you have a complaint about the product, this document or the conduct of the manufacturer, please contact Polar Capital's investor relations team via email: Investor-Relations@polarcapital.co.uk or call +44 (0) 207 227 2700. Alternatively, you can also write to Polar Capital, 16 Palace Street, London SW1E 5JD, United Kingdom.

Other relevant information

The Company's Annual and Interim Reports, historic Prospectus, and other corporate documentation, can be found in the Document Library of the Company's website: www.polarcapitalglobalhealthcaretrust.co.uk.